Diko Kazandjian

On Holy Fire day, Artsakh is with us. Always. We remember the 150,000 Christian Armenians who were ethnically cleansed by Azerbaijan, Turkey, and Israel. We remember our destroyed churches, our stolen homes, our desecrated land. We will always remember, and we will never forget. We will return. 301 Correspondent @kbalian90

Dr. Faith Davies on trispecifics and alternative targets ⁦@VJHemOnc⁩

@DrOlaLandgren on how Elra can be less frequently dosed @VJHemOnc

📢 SESSION IV at #MiamiMyelomaMRD26 Panel discussion on newly diagnosed multiple myeloma & MRD: what are the trends? Chaired by Ola Landgren (@DrOlaLandgren), with expert perspectives from leaders across academia, advocacy, and regulatory bodies #MultipleMyeloma #Myeloma #MMsm

The Miami Myeloma MRD Meeting is underway. First up is discussion on the role of MRD in smoldering myeloma. Data from CENTAURUS and AQUILA show very low rates of MRD negativity. Low intensity --> low rates of MRD(-)

🚨 MRD-guided treatment decisions in focus Benjamin Derman presents the MRD2STOP trial at #MiamiMyelomaMRD26 - shedding light on how MRD may inform when to stop therapy #MultipleMyeloma #Myeloma #MMsm

Join us for our Miami #Myeloma MRD Meeting 2026 🇺🇸 🩸 🗓️ Apr 10, 2026 The Miami Myeloma MRD Meeting 2026 is hosted by Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, University of Miami, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner 🧡 Agenda: 📌 Session 1: #MRDtesting in #smolderingmyeloma: new horizons 📌 Session 2: Panel discussion – Are all high-risk smoldering #myeloma patients offered therapy now? Role of depth of response? 📌 Session 3: New insights on MRD negativity in newly diagnosed #myeloma 📌 Session 4: Newly diagnosed #multiplemyeloma and #MRD: What are the trends 📌 Session 5: MRD driven treatment #trials 📌 Session 6: Panel discussion - MRD and treatment decisions: Are we there yet? 📌 Session 7: MRD in relapsed/refractory myeloma 📌 Session 8: The use of MRD in MMRFs clinical program 📌 Session 9: Emerging #MRDtechnologies 📌 Session 10: Emerging MRD technologies: What are the #clinical and scientific needs? REGISTER NOW to secure your spot 🔗 👉 us06web.zoom.us/webinar/regist… The continued success of the Miami Myeloma MRD meeting is in no small part due to the ongoing support of sponsors, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes. For more information about supporting Miami Myeloma MRD 2026, please contact us 👉 myelomamrd.org/supporter-oppo… Video Journal of Hematology & Hematological Oncology (VJHemOnc)

Thank you all that Donated to my 99miler Yesterday. Didn't do too bad 😎. FYI, it's not too late to still donate.

dolphinscancerchallenge.com/participant/Di… Please consider donating to Sylvester Cancer Center to support our research and my 99-mile bike ride ;)

Enjoying the beautiful weather and another awesome #DCCXVI with LLM and some GBM @JuanAlderuccio @macarenadelafuente @NimerLab @SylvesterCancer

Post ride lounge with @JTrentMDPhD @NimerLab @SylvesterCancer #DCCXVI

A little recovery after the 100 miler @SylvesterCancer @NimerLab @KobetzErin #DCCXVI

Rep. David Valadao (R-CA): "As co-chair of the Congressional Armenian Caucus, I’m proud to join my colleagues in introducing the Armenia Security Partnership Act. Azerbaijan’s aggression in the South Caucasus has gone on for far too long, and this bipartisan bill takes meaningful steps to hold them accountable for ongoing human rights abuses and hostilities against the sovereign territory of Armenia." The ANCA thanks @repdavidvaladao for being an original cosponsor of the ARMENIA Security Partnership Act, a bipartisan bill - backed by the ANCA - that seeks to restrict US military aid to Azerbaijan unless it takes demonstrable, concrete steps toward peace with Armenia. To learn more and ask your U.S. Representative to cosponsor the ARMENIA Security Partnership Act, visit anca.org/ArmeniaAct #ARMENIASecurity #StopAliyev #RealPeace #Accountability

Interim results from a Sylvester-led clinical trial show that an immune- and cancer-cell–targeting antibody therapy may eradicate residual traces of multiple myeloma. None of the 18 patients who completed up to six cycles of the bispecific antibody linvoseltamab had detectable disease on highly sensitive tests. Lead researcher Dr. Dickran Kazandjian presented the updated findings at the @ASH_hematology annual meeting, in collaboration with @DrOlaLandgren, as senior author. Based on its performance so far, the team hopes linvoseltamab could offer patients more durable responses than transplants, perhaps providing long-term control over the disease — a “functional cure.” Learn more: loom.ly/fORJKoA. #MMsm

Researchers are studying a promising new treatment strategy for people with relapsed or refractory multiple myeloma. The phase 2 ReKInDLE study is evaluating a four-drug combination designed to overcome resistance to lenalidomide. At the 67th @ASH_hematology Annual Meeting, Dr. Benjamin Diamond (@BenDiamondMD) presented early results showing that the quadruplet regimen is both active and well tolerated. Findings suggest that the ReKInDLE regimen could become an important option for patients facing early relapse. Updated data, including deeper MRD assessments, will continue to shape how this strategy fits into the evolving landscape of myeloma care. @DrOlaLandgren

Dr. Benjamin Diamond (@BenDiamondMD) presented "A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study" at #ASH25. Learn more: Sylvester.org/ASH25

Dr Kazandjian presenting latest results of the IMMUNOPLANT Study at #ASH25 — moving from transplant to #immunotherapy for #myeloma consolidation @dikokaz #MMsm

IMMUNOPLANT: Linvo x 4-6 cycles for patients with MRD positivity following induction. Patients then resumed lenalidomide. Essentially 100% MRD negativity rate following linvo consolidation and at 6 months after completion of linvo. This is really a remarkable result and speaks to the incredibly deep efficacy of bispecifics upfront. The big question is whether these deep responses will persist over time.

Dr. Benjamin Diamond (@BenDiamondMD) will present new findings from the ReKInDLE study at #ASH25, presenting a potential path forward for early relapse/refractory #MultipleMyeloma patients. Learn more about our presence: Sylvester.org/ASH25.

Dr. Dickran Kazandjian will share new findings from the IMMUNOPLANT study at #ASH25, a Phase 2 trial designed for newly diagnosed #MultipleMyeloma patients who remain MRD-positive after therapy, marking an important step toward more effective therapies. #MRD. Learn more about our presence: Sylvester.org/ASH25.